Compare Walt Disney Co (DIS) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Walt Disney Co vs Incyte Corporation — how do they compare? Walt Disney Co trades at $107.72 (market cap $184.79B), while Incyte Corporation trades at $113.03 (market cap $22.85B). The key difference: Walt Disney Co is far larger — about 8.1× Incyte Corporation's market cap, and Walt Disney Co pays a 1.4% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Walt Disney Co for 199 Days and Incyte Corporation for 33 Days on average.
| DIS | INCY | |
|---|---|---|
Market Cap | $184.79B | $22.85B |
Volume | 13,033,550 | 1,927,029 |
Sector | Media | Health |
52-Week High | $116.65 | $129.93 |
52-Week Low | $92.40 | $83.80 |
Typical Hold Time | 199 Days | 33 Days |
Enterprise Value | $225.65B | $18.35B |
Dividend Yield | 1.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Disney (DIS) trades at $104.76, up 0.7% with a bullish technical signal supported by moving averages. The company shows strong fundamental momentum with three consecutive quarterly earnings beats and robust revenue growth reaching $94.43 billion in 2025. Disney's net income margin expanded significantly to 13.13% while maintaining a reasonable P/E ratio of 22.07. Recent news highlights the company's $60 billion parks investment and streaming margin improvements above 13%.
Disney presents a compelling investment case with analyst consensus pointing to 20% upside to the $125.67 price target. The company's diversified entertainment ecosystem and accelerating DTC profitability support growth, though risks include free cash flow pressure from elevated investments and competitive streaming landscape. Institutional sentiment remains positive with 62.5% buy ratings among 64 analysts covering the stock.
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.
Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Walt Disney Co
The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.
Read more on DIS →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
